§ — Researched for · Aging pathways & mitochondrial function
The peptides marketed for 'aging itself' — epitalon, MOTS-c, and mitochondrial-derived peptides — have no controlled human outcome data. In July 2026, FDA proposed not to list either epitalon or MOTS-c for compounding, citing insufficient evidence.
Reviewed September 2026 · Sources: FDA, EMA
02 — What is being studied
This is the most mechanistic corner of peptide research. Mitochondrial-derived peptides encoded in mitochondrial DNA, such as MOTS-c, are studied for AMPK signalling, insulin sensitivity and exercise capacity in rodents and cell models. Epitalon is studied for pineal and telomerase-related mechanisms, largely in Russian-language work from the 1990s and 2000s.
The endpoints that would matter for an aging claim — survival, incidence of age-related disease, validated aging biomarkers measured against placebo in people — have not been studied for either compound. What exists is pathway data in animals and open-label human observation. Both were reviewed by FDA's compounding advisory committee in July 2026 and both were proposed for exclusion from the 503A Bulks List, which is the clearest available summary of the evidence base as of September 2026.
03 — The table
| Peptide | Researched for | Evidence | Regulatory status | As of |
|---|---|---|---|---|
| MOTS-c | Insulin sensitivity, exercise capacity, metabolic regulation, aging biology. | C | Not FDA-approved. Reviewed by PCAC on July 23, 2026; FDA proposed not to add it to the 503A Bulks List. Not eligible for compounding. | 2026-09-06 |
| Epitalon | Telomerase activation, melatonin regulation, lifespan extension. | D | Not FDA-approved. Reviewed by PCAC on July 24, 2026; FDA proposed not to add it to the 503A Bulks List. | 2026-09-06 |
04 — Per peptide
Regulatory status · United States · as of September 2026
Not FDA-approved. Reviewed by PCAC on July 23, 2026; FDA proposed not to add it to the 503A Bulks List. Not eligible for compounding.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
Researched forInsulin sensitivity, exercise capacity, metabolic regulation, aging biology.
Full profile: MOTS-c →Regulatory status · United States · as of September 2026
Not FDA-approved. Reviewed by PCAC on July 24, 2026; FDA proposed not to add it to the 503A Bulks List.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
Researched forTelomerase activation, melatonin regulation, lifespan extension.
Full profile: Epitalon →05 — What the data does not show
Life extension, telomere lengthening or reversal of aging markers in humans have not been shown for any peptide.
06 — Questions for your physician
Listing in the registry is not an endorsement of any substance or protocol, and it is not a statement that a treatment is approved.
Reviewed September 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.